The presence of coronary artery calcification (CAC) increases with age, leading to a higher number and complexity of percutaneous coronary intervention (PCI) procedures in older patients. Chronic kidney disease (CKD) and diabetes are also associated with the development of CAC. These significant comorbidities, combined with PCI of severely calcified lesions, pose major challenges due to technical difficulties and potentially compromise both short- and long-term outcomes. Patients undergoing PCI for heavily calcified lesions should receive optimal anticoagulation and antiplatelet therapy according to current guidelines. However, data on the potential use of more potent P2Y12 inhibitors (ticagrelor, prasugrel) instead of clopidogrel as standard practice in elective PCI of CAC are limited. This is due to varying classifications used to define complex PCI in meta-analyses, and the extreme heterogeneity of the populations studied in terms of clinical presentation. The duration of antiplatelet therapy with aspirin and a P2Y12 inhibitor can be prolonged in selected patients. However, there is increasing evidence supporting the validity of P2Y12 inhibitor monotherapy after standard DAPT, adopting an aspirin-free and tailored de-escalation strategy.
Citation: Giulia Alagna, Alessia Cascone, Antonino Micari, Giancarlo Trimarchi, Francesca Campanella, Giovanni Taverna, Saro Pistorio, Giuseppe Andò. Type and duration of antithrombotic therapy after treatment of severely calcified lesions[J]. AIMS Medical Science, 2025, 12(1): 38-62. doi: 10.3934/medsci.2025004
[1] | Muhammad Asim, Ghada AlNemer . Boundedness on variable exponent Morrey-Herz space for fractional multilinear Hardy operators. AIMS Mathematics, 2025, 10(1): 117-136. doi: 10.3934/math.2025007 |
[2] | Jie Sun, Jiamei Chen . Weighted estimates for commutators associated to singular integral operator satisfying a variant of Hörmander's condition. AIMS Mathematics, 2023, 8(11): 25714-25728. doi: 10.3934/math.20231311 |
[3] | Kieu Huu Dung, Do Lu Cong Minh, Pham Thi Kim Thuy . Commutators of Hardy-Cesàro operators on Morrey-Herz spaces with variable exponents. AIMS Mathematics, 2022, 7(10): 19147-19166. doi: 10.3934/math.20221051 |
[4] | Yueping Zhu, Yan Tang, Lixin Jiang . Boundedness of multilinear Calderón-Zygmund singular operators on weighted Lebesgue spaces and Morrey-Herz spaces with variable exponents. AIMS Mathematics, 2021, 6(10): 11246-11262. doi: 10.3934/math.2021652 |
[5] | Wanjing Zhang, Suixin He, Jing Zhang . Boundedness of sublinear operators on weighted grand Herz-Morrey spaces. AIMS Mathematics, 2023, 8(8): 17381-17401. doi: 10.3934/math.2023888 |
[6] | Babar Sultan, Mehvish Sultan, Qian-Qian Zhang, Nabil Mlaiki . Boundedness of Hardy operators on grand variable weighted Herz spaces. AIMS Mathematics, 2023, 8(10): 24515-24527. doi: 10.3934/math.20231250 |
[7] | Javeria Younas, Amjad Hussain, Hadil Alhazmi, A. F. Aljohani, Ilyas Khan . BMO estimates for commutators of the rough fractional Hausdorff operator on grand-variable-Herz-Morrey spaces. AIMS Mathematics, 2024, 9(9): 23434-23448. doi: 10.3934/math.20241139 |
[8] | Ming Liu, Bin Zhang, Xiaobin Yao . Weighted variable Morrey-Herz space estimates for $ m $th order commutators of $ n- $dimensional fractional Hardy operators. AIMS Mathematics, 2023, 8(9): 20063-20079. doi: 10.3934/math.20231022 |
[9] | Shuhui Yang, Yan Lin . Multilinear strongly singular integral operators with generalized kernels and applications. AIMS Mathematics, 2021, 6(12): 13533-13551. doi: 10.3934/math.2021786 |
[10] | Naqash Sarfraz, Muhammad Aslam . Some weighted estimates for the commutators of $p$-adic Hardy operator on two weighted $p$-adic Herz-type spaces. AIMS Mathematics, 2021, 6(9): 9633-9646. doi: 10.3934/math.2021561 |
The presence of coronary artery calcification (CAC) increases with age, leading to a higher number and complexity of percutaneous coronary intervention (PCI) procedures in older patients. Chronic kidney disease (CKD) and diabetes are also associated with the development of CAC. These significant comorbidities, combined with PCI of severely calcified lesions, pose major challenges due to technical difficulties and potentially compromise both short- and long-term outcomes. Patients undergoing PCI for heavily calcified lesions should receive optimal anticoagulation and antiplatelet therapy according to current guidelines. However, data on the potential use of more potent P2Y12 inhibitors (ticagrelor, prasugrel) instead of clopidogrel as standard practice in elective PCI of CAC are limited. This is due to varying classifications used to define complex PCI in meta-analyses, and the extreme heterogeneity of the populations studied in terms of clinical presentation. The duration of antiplatelet therapy with aspirin and a P2Y12 inhibitor can be prolonged in selected patients. However, there is increasing evidence supporting the validity of P2Y12 inhibitor monotherapy after standard DAPT, adopting an aspirin-free and tailored de-escalation strategy.
Let T be the Calderón-Zygmund singular integral operator and b be a locally integrable function on Rn. The commutator generated by b and T is defined by [b,T]f=bT(f)−T(bf). The investigation of the commutator begins with Coifman-Rochberg-Weiss pioneering study and classical result (see [6]). The classical result of Coifman, Rochberg and Weiss (see [6]) states that the commutator [b,T]f=T(bf)−bTf is bounded on Lp(Rn) for 1<p<∞ if and only if b∈BMO(Rn). The major reason for considering the problem of commutators is that the boundedness of commutator can produces some characterizations of function spaces (see [1,6]). Chanillo (see [1]) proves a similar result when T is replaced by the fractional integral operator. In [11], the boundedness properties of the commutators for the extreme values of p are obtained. In recent years, the theory of Herz space and Herz type Hardy space, as a local version of Lebesgue space and Hardy space, have been developed (see [8,9,12,13]). The main purpose of this paper is to establish the endpoint continuity properties of some multilinear operators related to certain non-convolution type fractional singular integral operators on Herz and Herz type Hardy spaces.
First, let us introduce some notations (see [8,9,10,12,13,15]). Throughout this paper, Q will denote a cube of Rn with sides parallel to the axes. For a cube Q and a locally integrable function f, let fQ=|Q|−1∫Qf(x)dx and f#(x)=supQ∋x|Q|−1∫Q|f(y)−fQ|dy. Moreover, f is said to belong to BMO(Rn) if f#∈L∞ and define ||f||BMO=||f#||L∞; We also define the central BMO space by CMO(Rn), which is the space of those functions f∈Lloc(Rn) such that
||f||CMO=supr>1|Q(0,r)|−1∫Q|f(y)−fQ|dy<∞. |
It is well-known that (see [9,10])
||f||CMO≈supr>1infc∈C|Q(0,r)|−1∫Q|f(x)−c|dx. |
For k∈Z, define Bk={x∈Rn:|x|≤2k} and Ck=Bk∖Bk−1. Denote by χk the characteristic function of Ck and ˜χk the characteristic function of Ck for k≥1 and ˜χ0 the characteristic function of B0.
Definition 1. Let 0<p<∞ and α∈R.
(1) The homogeneous Herz space ˙Kαp(Rn) is defined by
˙Kαp(Rn)={f∈Lploc(Rn∖{0}):||f||˙Kαp<∞}, |
where
||f||˙Kαp=∞∑k=−∞2kα||fχk||Lp; |
(2) The nonhomogeneous Herz space Kαp(Rn) is defined by
Kαp(Rn)={f∈Lploc(Rn):||f||Kαp<∞}, |
where
||f||Kαp=∞∑k=02kα||f˜χk||Lp. |
If α=n(1−1/p), we denote that ˙Kαp(Rn)=˙Kp(Rn), Kαp(Rn)=Kp(Rn).
Definition 2. Let 0<δ<n and 1<p<n/δ. We shall call Bδp(Rn) the space of those functions f on Rn such that
||f||Bδp=supd>1d−n(1/p−δ/n)||fχQ(0,d)||Lp<∞. |
Definition 3. Let 1<p<∞.
(1) The homogeneous Herz type Hardy space H˙Kp(Rn) is defined by
H˙Kp(Rn)={f∈S′(Rn):G(f)∈˙Kp(Rn)}, |
where
||f||H˙Kp=||G(f)||˙Kp. |
(2) The nonhomogeneous Herz type Hardy space HKp(Rn) is defined by
HKp(Rn)={f∈S′(Rn):G(f)∈Kp(Rn)}, |
where
||f||HKp=||G(f)||Kp. |
where G(f) is the grand maximal function of f.
The Herz type Hardy spaces have the atomic decomposition characterization.
Definition 4. Let 1<p<∞. A function a(x) on Rn is called a central (n(1−1/p),p)-atom (or a central (n(1−1/p),p)-atom of restrict type), if
1) Suppa⊂B(0,d) for some d>0 (or for some d≥1),
2) ||a||Lp≤|B(0,d)|1/p−1,
3) ∫a(x)dx=0.
Lemma 1. (see [9,13]) Let 1<p<∞. A temperate distribution f belongs to H˙Kp(Rn)(or HKp(Rn)) if and only if there exist central (n(1−1/p),p)-atoms(or central (n(1−1/p),p)-atoms of restrict type) aj supported on Bj=B(0,2j) and constants λj, ∑j|λj|<∞ such that f=∑∞j=−∞λjaj (or f=∑∞j=0λjaj)in the S′(Rn) sense, and
||f||H˙Kp( or ||f||HKp)≈∑j|λj|. |
In this paper, we will consider a class of multilinear operators related to some non-convolution type singular integral operators, whose definition are following.
Let m be a positive integer and A be a function on Rn. We denote that
Rm+1(A;x,y)=A(x)−∑|β|≤m1β!DβA(y)(x−y)β |
and
Qm+1(A;x,y)=Rm(A;x,y)−∑|β|=m1β!DβA(x)(x−y)β. |
Definition 5. Fixed ε>0 and 0<δ<n. Let Tδ:S→S′ be a linear operator. Tδ is called a fractional singular integral operator if there exists a locally integrable function K(x,y) on Rn×Rn such that
Tδ(f)(x)=∫RnK(x,y)f(y)dy |
for every bounded and compactly supported function f, where K satisfies:
|K(x,y)|≤C|x−y|−n+δ |
and
|K(y,x)−K(z,x)|+|K(x,y)−K(x,z)|≤C|y−z|ε|x−z|−n−ε+δ |
if 2|y−z|≤|x−z|. The multilinear operator related to the fractional singular integral operator Tδ is defined by
TAδ(f)(x)=∫RnRm+1(A;x,y)|x−y|mK(x,y)f(y)dy; |
We also consider the variant of TAδ, which is defined by
˜TAδ(f)(x)=∫RnQm+1(A;x,y)|x−y|mK(x,y)f(y)dy. |
Note that when m=0, TAδ is just the commutators of Tδ and A (see [1,6,11,14]). It is well known that multilinear operator, as a non-trivial extension of commutator, is of great interest in harmonic analysis and has been widely studied by many authors (see [3,4,5]). In [7], the weighted Lp(p>1)-boundedness of the multilinear operator related to some singular integral operator are obtained. In [2], the weak (H1, L1)-boundedness of the multilinear operator related to some singular integral operator are obtained. In this paper, we will study the endpoint continuity properties of the multilinear operators TAδ and ˜TAδ on Herz and Herz type Hardy spaces.
Now we state our results as following.
Theorem 1. Let 0<δ<n, 1<p<n/δ and DβA∈BMO(Rn) for all β with |β|=m. Suppose that TAδ is the same as in Definition 5 such that Tδ is bounded from Lp(Rn) to Lq(Rn) for any p,q∈(1,+∞] with 1/q=1/p−δ/n. Then TAδ is bounded from Bδp(Rn) to CMO(Rn).
Theorem 2. Let 0<δ<n, 1<p<n/δ, 1/q=1/p−δ/n and DβA∈BMO(Rn) for all β with |β|=m. Suppose that ˜TAδ is the same as in Definition 5 such that ˜TAδ is bounded from Lp(Rn) to Lq(Rn) for any p,q∈(1,+∞) with 1/q=1/p−δ/n. Then ˜TAδ is bounded from H˙Kp(Rn) to ˙Kαq(Rn) with α=n(1−1/p).
Theorem 3. Let 0<δ<n, 1<p<n/δ and DβA∈BMO(Rn) for all β with |β|=m. Suppose that ˜TAδ is the same as in Definition 5 such that ˜TAδ is bounded from Lp(Rn) to Lq(Rn) for any p,q∈(1,+∞) with 1/q=1/p−δ/n. Then the following two statements are equivalent:
(ⅰ) ˜TAδ is bounded from Bδp(Rn) to CMO(Rn);
(ⅱ) for any cube Q and z∈3Q∖2Q, there is
1|Q|∫Q|∑|β|=m1β!|DβA(x)−(DβA)Q|∫(4Q)cKβ(z,y)f(y)dy|dx≤C||f||Bδp, |
where Kβ(z,y)=(z−y)β|z−y|mK(z,y) for |β|=m.
Remark. Theorem 2 is also hold for nonhomogeneous Herz and Herz type Hardy space.
To prove the theorem, we need the following lemma.
Lemma 2. (see [5]) Let A be a function on Rn and DβA∈Lq(Rn) for |β|=m and some q>n. Then
|Rm(A;x,y)|≤C|x−y|m∑|β|=m(1|˜Q(x,y)|∫˜Q(x,y)|DβA(z)|qdz)1/q, |
where ˜Q(x,y) is the cube centered at x and having side length 5√n|x−y|.
Proof of Theorem 1. It suffices to prove that there exists a constant CQ such that
1|Q|∫Q|TAδ(f)(x)−CQ|dx≤C||f||Bδp |
holds for any cube Q=Q(0,d) with d>1. Fix a cube Q=Q(0,d) with d>1. Let ˜Q=5√nQ and ˜A(x)=A(x)−∑|β|=m1β!(DβA)˜Qxβ, then Rm+1(A;x,y)=Rm+1(˜A;x,y) and Dβ˜A=DβA−(DβA)˜Q for all β with |β|=m. We write, for f1=fχ˜Q and f2=fχRn∖˜Q,
TAδ(f)(x)=∫RnRm+1(˜A;x,y)|x−y|mK(x,y)f(y)dy=∫RnRm(˜A;x,y)|x−y|mK(x,y)f1(y)dy−∑|β|=m1β!∫RnK(x,y)(x−y)β|x−y|mDβ˜A(y)f1(y)dy+∫RnRm+1(˜A;x,y)|x−y|mK(x,y)f2(y)dy, |
then
1|Q|∫Q|TAδ(f)(x)−T˜Aδ(f2)(0)|dx≤1|Q|∫Q|Tδ(Rm(˜A;x,⋅)|x−⋅|mf1)(x)|dx+∑|β|=m1β!1|Q|∫Q|Tδ((x−⋅)β|x−⋅|mDβ˜Af1)(x)|dx+|T˜Aδ(f2)(x)−T˜Aδ(f2)(0)|dx:=I+II+III. |
For I, note that for x∈Q and y∈˜Q, using Lemma 2, we get
Rm(˜A;x,y)≤C|x−y|m∑|β|=m||DβA||BMO, |
thus, by the Lp(Rn) to Lq(Rn)-boundedness of TAδ for 1<p,q<∞ with 1/q=1/p−δ/n, we get
I≤C|Q|∫Q|Tδ(∑|β|=m||DβA||BMOf1)(x)|dx≤C∑|β|=m||DβA||BMO(1|Q|∫Q|Tδ(f1)(x)|qdx)1/q≤C∑|β|=m||DβA||BMO|Q|−1/q||f1||Lp≤C∑|β|=m||DβA||BMOr−n(1/p−δ/n)||fχ˜Q||Lp≤C∑|β|=m||DβA||BMO||f||Bδp. |
For II, taking 1<s<p such that 1/r=1/s−δ/n, by the (Ls,Lr)-boundedness of Tδ and Holder's inequality, we gain
II≤C|Q|∫Q|Tδ(∑|β|=m(DβA−(DβA)˜Q)f1)(x)|dx≤C∑|β|=m(1|Q|∫Q|Tδ((DβA−(DβA)˜Q)f1)(x)|rdx)1/r≤C|Q|−1/r∑|β|=m||(DβA−(DβA)˜Q)f1||Ls≤C|Q|−1/r||f1||Lp∑|β|=m(1|Q|∫˜Q|DβA(y)−(DβA)˜Q|ps/(p−s)dy)(p−s)/(ps)|Q|(p−s)/(ps)≤C∑|β|=m||DβA||BMOr−n/q||fχ˜Q||Lp≤C∑|β|=m||DβA||BMO||f||Bδp. |
To estimate III, we write
T˜Aδ(f2)(x)−T˜Aδ(f2)(0)=∫Rn[K(x,y)|x−y|m−K(0,y)|y|m]Rm(˜A;x,y)f2(y)dy+∫RnK(0,y)f2(y)|y|m[Rm(˜A;x,y)−Rm(˜A;0,y)]dy−∑|β|=m1β!∫Rn(K(x,y)(x−y)β|x−y|m−K(0,y)(−y)β|y|m)Dβ˜A(y)f2(y)dy:=III1+III2+III3. |
By Lemma 2 and the following inequality (see [15])
|bQ1−bQ2|≤Clog(|Q2|/|Q1|)||b||BMO for Q1⊂Q2, |
we know that, for x∈Q and y∈2k+1˜Q∖2k˜Q,
|Rm(˜A;x,y)|≤C|x−y|m∑|β|=m(||DβA||BMO+|(DβA)˜Q(x,y)−(DβA)˜Q|)≤Ck|x−y|m∑|β|=m||DβA||BMO. |
Note that |x−y|∼|y| for x∈Q and y∈Rn∖˜Q, we obtain, by the condition of K,
|III1|≤C∫Rn(|x||y|m+n+1−δ+|x|ε|y|m+n+ε−δ)|Rm(˜A;x,y)||f2(y)|dy≤C∑|β|=m||DβA||BMO∞∑k=0∫2k+1˜Q∖2k˜Qk(|x||y|n+1−δ+|x|ε|y|n+ε−δ)|f(y)|dy≤C∑|β|=m||DβA||BMO∞∑k=1k(2−k+2−εk)(2kr)−n(1/p−δ/n)||fχ2k˜Q||Lp≤C∑|β|=m||DβA||BMO∞∑k=1k(2−k+2−εk)||f||Bδp≤C∑|β|=m||DβA||BMO||f||Bδp. |
For III2, by the formula (see [5]):
Rm(˜A;x,y)−Rm(˜A;x0,y)=∑|γ|<m1γ!Rm−|γ|(Dγ˜A;x,x0)(x−y)γ |
and Lemma 2, we have
|Rm(˜A;x,y)−Rm(˜A;x0,y)|≤C∑|γ|<m∑|β|=m|x−x0|m−|γ||x−y||γ|||DβA||BMO, |
thus, similar to the estimates of III1, we get
|III2|≤C∑|β|=m||DβA||BMO∞∑k=0∫2k+1˜Q∖2k˜Q|x||y|n+1−δ|f(y)|dy≤C∑|β|=m||DβA||BMO||f||Bδp. |
For III3, by Holder's inequality, similar to the estimates of III1, we get
|III3|≤C∑|β|=m∞∑k=0∫2k+1˜Q∖2k˜Q(|x||y|n+1−δ+|x|ε|y|n+ε−δ)|Dβ˜A(y)||f(y)|dy≤C∑|β|=m∞∑k=1(2−k+2−εk)(2kr)−n(1/p−δ/n)(|2k˜Q|−1∫2k˜Q|DβA(y)−(DβA)˜Q|p′dy)1/p′||fχ2k˜Q||Lp≤C∑|β|=m||DβA||BMO∞∑k=1(2−k+2−εk)(2kr)−n(1/p−δ/n)||fχ2k˜Q||Lp≤C∑|β|=m||DβA||BMO||f||Bδp. |
Thus
III≤C∑|β|=m||DβA||BMO||f||Bδp, |
which together with the estimates for I and II yields the desired result. This finishes the proof of Theorem 1.
Proof of Theorem 2. Let f∈H˙Kp(Rn), by Lemma 1, f=∑∞j=−∞λjaj, where a′js are the central (n(1−1/p),p)-atom with suppaj⊂Bj=B(0,2j) and ||f||H˙Kp≈∑j|λj|. We write
||˜TAδ(f)||˙Kαq=∞∑k=−∞2kn(1−1/p)||χk˜TAδ(f)||Lq≤∞∑k=−∞2kn(1−1/p)k−1∑j=−∞|λj|||χk˜TAδ(aj)||Lq+∞∑k=−∞2kn(1−1/p)∞∑j=k|λj|||χk˜TAδ(aj)||Lq=J+JJ. |
For JJ, by the (Lp,Lq)-boundedness of ˜TAδ for 1/q=1/p−δ/n, we get
JJ≤C∞∑k=−∞2kn(1−1/p)∞∑j=k|λj|||aj||Lp≤C∞∑k=−∞2kn(1−1/p)∞∑j=k|λj|2jn(1/p−1)≤C∞∑j=−∞|λj|j∑k=−∞2(k−j)n(1−1/p)≤C∞∑j=−∞|λj|≤C||f||H˙Kp. |
To obtain the estimate of J, we denote that ˜A(x)=A(x)−∑|β|=m1β!(DβA)2Bjxβ. Then Qm(A;x,y)=Qm(˜A;x,y) and Qm+1(A;x,y)=Rm(A;x,y)−∑|β|=m1β!(x−y)βDβA(x). We write, by the vanishing moment of a and for x∈Ck with k≥j+1,
˜TAδ(aj)(x)=∫RnK(x,y)Rm(A;x,y)|x−y|maj(y)dy−∑|β|=m1β!∫RnK(x,y)Dβ˜A(x)(x−y)β|x−y|maj(y)dy=∫Rn[K(x,y)|x−y|m−K(x,0)|x|m]Rm(˜A;x,y)aj(y)dy+∫RnK(x,0)|x|m[Rm(˜A;x,y)−Rm(˜A;x,0)]aj(y)dy−∑|β|=m1β!∫Rn[K(x,y)(x−y)β|x−y|m−K(x,0)xβ|x|m]Dβ˜A(x)aj(y)dy. |
Similar to the proof of Theorem 1, we obtain
|˜TAδ(aj)(x)|≤C∫Rn[|y||x|m+n+1−δ+|y|ε|x|m+n+ε−δ]|Rm(˜A;x,y)||aj(y)|dy+C∑|β|=m∫Rn[|y||x|n+1−δ+|y|ε|x|n+ε−δ]|Dβ˜A(x)||aj(y)|dy≤C∑|β|=m||DβA||BMO[2j2k(n+1−δ)+2jε2k(n+ε−δ)]+C∑|β|=m[2j2k(n+1−δ)+2jε2k(n+ε−δ)]|Dβ˜A(x)|, |
thus
J≤C∑|β|=m||DβA||BMO∞∑k=−∞2kn(1−1/p)k−1∑j=−∞|λj|[2j2k(n+1−δ)+2jε2k(n+ε−δ)]2kn/q+C∑|β|=m∞∑k=−∞2kn(1−1/p)k−1∑j=−∞|λj|[2j2k(n+1−δ)+2jε2k(n+ε−δ)](∫Bk|Dβ˜A(x)|qdx)1/q≤C∑|β|=m||DβA||BMO∞∑k=−∞2kn(1−δ/n)k−1∑j=−∞|λj|[2j2k(n+1−δ)+2jε2k(n+ε−δ)]≤C∑|β|=m||DβA||BMO∞∑j=−∞|λj|∞∑k=j+1[2j−k+2(j−k)ε]≤C∑|β|=m||DβA||BMO∞∑j=−∞|λj|≤C∑|β|=m||DβA||BMO||f||H˙Kp. |
This completes the proof of Theorem 2.
Proof of Theorem 3. For any cube Q=Q(0,r) with r>1, let f∈Bδp and ˜A(x)=A(x)−∑|β|=m1β!(DβA)˜Qxβ. We write, for f=fχ4Q+fχ(4Q)c=f1+f2 and z∈3Q∖2Q,
˜TAδ(f)(x)=˜TAδ(f1)(x)+∫RnRm(˜A;x,y)|x−y|mK(x,y)f2(y)dy−∑|β|=m1β!(DβA(x)−(DβA)Q)(Tδ,β(f2)(x)−Tδ,β(f2)(z))−∑|β|=m1β!(DβA(x)−(DβA)Q)Tδ,β(f2)(z)=I1(x)+I2(x)+I3(x,z)+I4(x,z), |
where Tδ,β is the singular integral operator with the kernel (x−y)β|x−y|mK(x,y) for |β|=m. Note that (I4(⋅,z))Q=0, we have
˜TAδ(f)(x)−(˜TAδ(f))Q=I1(x)−(I1(⋅))Q+I2(x)−I2(z)−[I2(⋅)−I2(z)]Q−I3(x,z)+(I3(x,z))Q−I4(x,z). |
By the (Lp,Lq)-bounded of ˜TAδ, we get
1|Q|∫Q|I1(x)|dx≤(1|Q|∫Q|˜TAδ(f1)(x)|qdx)1/q≤C|Q|−1/q||f1||Lp≤C||f||Bδp. |
Similar to the proof of Theorem 1, we obtain
|I2(x)−I2(z)|≤C||f||Bδp |
and
1|Q|∫Q|I3(x,z)|dx≤C||f||Bδp. |
Then integrating in x on Q and using the above estimates, we obtain the equivalence of the estimate
1|Q|∫Q|˜TAδ(f)(x)−(˜TAδ(f))Q|dx≤C||f||Bδp |
and the estimate
1|Q|∫Q|I4(x,z)|dx≤C||f||Bδp. |
This completes the proof of Theorem 3.
In this section we shall apply the theorems of the paper to some particular operators such as the Calderón-Zygmund singular integral operator and fractional integral operator.
Application 1. Calderón-Zygmund singular integral operator.
Let T be the Calderón-Zygmund operator defined by (see [10,11,15])
T(f)(x)=∫RnK(x,y)f(y)dy, |
the multilinear operator related to T is defined by
TA(f)(x)=∫RnRm+1(A;x,y)|x−y|mK(x,y)f(y)dy. |
Then it is easily to see that T satisfies the conditions in Theorems 1–3, thus the conclusions of Theorems 1–3 hold for TA.
Application 2. Fractional integral operator with rough kernel.
For 0<δ<n, let Tδ be the fractional integral operator with rough kernel defined by (see [2,7])
Tδf(x)=∫RnΩ(x−y)|x−y|n−δf(y)dy, |
the multilinear operator related to Tδ is defined by
TAδf(x)=∫RnRm+1(A;x,y)|x−y|m+n−δΩ(x−y)f(y)dy, |
where Ω is homogeneous of degree zero on Rn, ∫Sn−1Ω(x′)dσ(x′)=0 and Ω∈Lipε(Sn−1) for some 0<ε≤1, that is there exists a constant M>0 such that for any x,y∈Sn−1, |Ω(x)−Ω(y)|≤M|x−y|ε. Then Tδ satisfies the conditions in Theorem 1. In fact, for suppf⊂(2Q)c and x∈Q=Q(x0,d), by the condition of Ω, we have (see [16])
|Ω(x−y)|x−y|n−δ−Ω(x0−y)|x0−y|n−δ|≤C(|x−x0|ε|x0−y|n+ε−δ+|x−x0||x0−y|n+1−δ), |
thus, the conclusions of Theorems 1–3 hold for TAδ.
The author would like to express his deep gratitude to the referee for his/her valuable comments and suggestions. This research was supported by the National Natural Science Foundation of China (Grant No. 11901126), the Scientific Research Funds of Hunan Provincial Education Department. (Grant No. 19B509).
The authors declare that they have no competing interests.
[1] |
Wong ND, Kouwabunpat D, Vo AN, et al. (1994) Coronary calcium and atherosclerosis by ultrafast computed tomography in asymptomatic men and women: relation to age and risk factors. Am Heart J 127: 422-430. https://doi.org/10.1016/0002-8703(94)90133-3 ![]() |
[2] |
Kedhi E, Généreux P, Palmerini T, et al. (2014) Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol 63: 2111-2118. https://doi.org/10.1016/j.jacc.2014.01.064 ![]() |
[3] |
Wang XR, Zhang JJ, Xu XX, et al. (2019) Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail 41: 244-256. https://doi.org/10.1080/0886022X.2019.1595646 ![]() |
[4] | Roy SK, Cespedes A, Li D, et al. (2011) Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium. Vasc Health Risk Manag 7: 719-724. https://doi.org/10.2147/VHRM.S24536 |
[5] |
Généreux P, Madhavan MV, Mintz GS, et al. (2014) Ischemic outcomes after coronary intervention of calcified vessels in acute coronary syndromes. Pooled analysis from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trials. J Am Coll Cardiol 63: 1845-1854. https://doi.org/10.1016/j.jacc.2014.01.034 ![]() |
[6] |
Madhavan MV, Tarigopula M, Mintz GS, et al. (2014) Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol 63: 1703-1714. https://doi.org/10.1016/j.jacc.2014.01.017 ![]() |
[7] | Hu YC, Chen WJ, Lai CH, et al. (2023) Rotablation for octogenarians in a modern Cathlab: short- and intermediate-term results. Acta Cardiol Sin 39: 424-434. https://doi.org/10.6515/ACS.202305_39(3).20220926B |
[8] |
Valgimigli M, Bueno H, Byrne RA, et al. (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39: 213-260. https://doi.org/10.1093/eurheartj/ehx419 ![]() |
[9] |
Riley RF, Henry TD, Mahmud E, et al. (2020) SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv 96: 346-362. https://doi.org/10.1002/ccd.28994 ![]() |
[10] |
Zeitouni M, Silvain J, Guedeney P, et al. (2018) Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J 39: 1100-1109. https://doi.org/10.1093/eurheartj/ehx799 ![]() |
[11] |
Ndrepepa G, Colleran R, Braun S, et al. (2016) High-sensitivity troponin T and mortality after elective percutaneous coronary intervention. J Am Coll Cardiol 68: 2259-2268. https://doi.org/10.1016/j.jacc.2016.08.059 ![]() |
[12] |
Prasad A, Singh M, Lerman A, et al. (2006) Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 48: 1765-1770. https://doi.org/10.1016/j.jacc.2006.04.102 ![]() |
[13] |
Xu Q, Sun Y, Zhang Y, et al. (2017) Effect of a 180 mg ticagrelor loading dose on myocardial necrosis in patients undergoing elective percutaneous coronary intervention: a preliminary study. Cardiol J 24: 15-24. https://doi.org/10.5603/CJ.a2017.0002 ![]() |
[14] |
Bonello L, Laine M, Thuny F, et al. (2016) Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. Int J Cardiol 216: 190-193. https://doi.org/10.1016/j.ijcard.2016.04.165 ![]() |
[15] |
Orme RC, Parker WAE, Thomas MR, et al. (2018) Study of two dose regimens of ticagrelor compared with clopidogrel in patients undergoing percutaneous coronary intervention for stable coronary artery disease. Circulation 138: 1290-1300. https://doi.org/10.1161/CIRCULATIONAHA.118.034790 ![]() |
[16] |
Khan MR, Koshy AN, Tanner R, et al. (2024) Real-world comparison of clopidogrel with ticagrelor and prasugrel in patients with chronic coronary disease who underwent atherectomy. Am J Cardiol 217: 1-4. https://doi.org/10.1016/j.amjcard.2024.02.006 ![]() |
[17] |
Dehmer GJ, Nichols TC, Bode AP, et al. (1997) Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. Am J Cardiol 80: 871-877. https://doi.org/10.1016/s0002-9149(97)00538-9 ![]() |
[18] |
Bau J, Gutensohn K, Kuck KH, et al. (2000) Flow-cytometric analysis of platelet activation during rotablation. Z Kardiol 89: 15-20. https://doi.org/10.1007/s003920050003 (Article in German) ![]() |
[19] |
Kini A, Kini S, Marmur JD, et al. (1999) Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheter Cardiovasc Interv 48: 123-129. https://doi.org/10.1002/(sici)1522-726x(199910)48:2<123::aid-ccd1>3.0.co;2-o ![]() |
[20] |
Sharma SK, Dangas G, Mehran R, et al. (1997) Risk factors for the development of slow flow during rotational coronary atherectomy. Am J Cardiol 80: 219-222. https://doi.org/10.1016/s0002-9149(97)00325-1 ![]() |
[21] |
Kini A, Marmur JD, Duvvuri S, et al. (1999) Rotational atherectomy: improved procedural outcome with evolution of technique and equipment. Single-center results of first 1000 patients. Catheter Cardiovasc Interv 46: 305-311. https://doi.org/10.1002/(SICI)1522-726X(199903)46:3<305::AID-CCD9>3.0.CO;2-U ![]() |
[22] |
Chieffo A, Latib A, Caussin C, et al. (2013) A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: the AVIO trial. Am Heart J 165: 65-72. https://doi.org/10.1016/j.ahj.2012.09.017 ![]() |
[23] |
Kirtane AJ, Doshi D, Leon MB, et al. (2016) Treatment of higher-risk patients with an indication for revascularization: evolution within the field of contemporary percutaneous coronary intervention. Circulation 134: 422-431. https://doi.org/10.1161/CIRCULATIONAHA.116.022061 ![]() |
[24] |
Giustino G, Chieffo A, Palmerini T, et al. (2016) Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol 68: 1851-1864. https://doi.org/10.1016/j.jacc.2016.07.760 ![]() |
[25] |
Yeh RW, Kereiakes DJ, Steg PG, et al. (2017) Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention. J Am Coll Cardiol 70: 2213-2223. https://doi.org/10.1016/j.jacc.2017.09.011 ![]() |
[26] |
Généreux P, Giustino G, Redfors B, et al. (2018) Impact of percutaneous coronary intervention extent, complexity and platelet reactivity on outcomes after drug-eluting stent implantation. Int J Cardiol 268: 61-67. https://doi.org/10.1016/j.ijcard.2018.03.103 ![]() |
[27] |
Chandrasekhar J, Baber U, Sartori S, et al. (2018) Associations between complex PCI and prasugrel or clopidogrel use in patients with acute coronary syndrome who undergo PCI: from the PROMETHEUS study. Can J Cardiol 34: 319-329. https://doi.org/10.1016/j.cjca.2017.12.023 ![]() |
[28] |
Lipiecki J, Brunel P, Morice MC, et al. (2018) Biolimus A9 polymer-free coated stents in high bleeding risk patients undergoing complex PCI: evidence from the LEADERS FREE randomised clinical trial. EuroIntervention 14: e418-e425. https://doi.org/10.4244/EIJ-D-18-00293 ![]() |
[29] |
Costa F, Van Klaveren D, Feres F, et al. (2019) Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol 73: 741-754. https://doi.org/10.1016/j.jacc.2018.11.048 ![]() |
[30] |
Choi KH, Song YB, Lee JM, et al. (2019) Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in patients undergoing complex procedures. JACC Cardiovasc Interv 12: 607-620. https://doi.org/10.1016/j.jcin.2019.01.227 ![]() |
[31] |
Henson KD, Popma JJ, Leon MB, et al. (1993) Comparison of results of rotational coronary atherectomy in three age groups (< 70, 70 to 79 and > or = 80 years). Am J Cardiol 71: 862-864. https://doi.org/10.1016/0002-9149(93)90839-5 ![]() |
[32] | Gravina Taddei CF, Weintraub WS, King 3rd S, et al. (1999) Early and intermediate outcomes after rotational atherectomy in octogenarian patients. Am J Geriatr Cardiol 8: 169-172. |
[33] |
Sandhu K, Nadar SK (2015) Percutaneous coronary intervention in the elderly. Int J Cardiol 199: 342-355. https://doi.org/10.1016/j.ijcard.2015.05.188 ![]() |
[34] | Shanmugam VB, Harper R, Meredith I, et al. (2015) An overview of PCI in the very elderly. J Geriatr Cardiol 12: 174-184. https://doi.org/10.11909/j.issn.1671-5411.2015.02.012 |
[35] |
Urban P, Gregson J, Owen R, et al. (2021) Assessing the risks of bleeding vs thrombotic events in patients at high bleeding risk after coronary stent implantation: the ARC–high bleeding risk trade-off model. JAMA Cardiol 6: 410-419. https://doi.org/10.1001/jamacardio.2020.6814 ![]() |
[36] |
Mohamed MO, Polad J, Hildick-Smith D, et al. (2020) Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry. EuroIntervention 16: 603-612. https://doi.org/10.4244/EIJ-D-20-00361 ![]() |
[37] |
Knuuti J, Wijns W, Saraste A, et al. (2020) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 41: 407-477. https://doi.org/10.1093/eurheartj/ehz425 ![]() |
[38] |
Byrne RA, Rossello X, Coughlan JJ, et al. (2023) 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J 44: 3720-3826. https://doi.org/10.1093/eurheartj/ehad191 ![]() |
[39] |
Lis P, Rajzer M, Klima Ł (2024) The Significance of coronary artery calcification for percutaneous coronary interventions. Healthcare 12: 520. https://doi.org/10.3390/healthcare12050520 ![]() |
[40] |
Baber U, Mehran R, Giustino G, et al. (2016) Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from Paris. J Am Coll Cardiol 67: 2224-2234. https://doi.org/10.1016/j.jacc.2016.02.064 ![]() |
[41] |
Raposeiras-Roubín S, Faxén J, Íñiguez-Romo A, et al. (2018) Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score. Int J Cardiol 254: 10-15. https://doi.org/10.1016/j.ijcard.2017.10.103 ![]() |
[42] |
Urban P, Mehran R, Colleran R, et al. (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 40: 2632-2653. https://doi.org/10.1093/eurheartj/ehz372 ![]() |
[43] |
Caiazzo G, Di Mario C, Kedhi E, et al. (2023) Current management of highly calcified coronary lesions: an overview of the current status. J Clin Med 12: 4844. https://doi.org/10.3390/jcm12144844 ![]() |
[44] |
Koo BK, Kang J, Park KW, et al. (2021) Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet 397: 2487-2496. https://doi.org/10.1016/S0140-6736(21)01063-1 ![]() |
[45] |
Capodanno D, Angiolillo DJ (2023) Long-term P2Y12 inhibitor or aspirin as single antiplatelet therapy in patients with previous percutaneous coronary intervention. Circulation 147: 118-121. https://doi.org/10.1161/CIRCULATIONAHA.122.063004 ![]() |
[46] |
Andò G, De Santis GA, Greco A, et al. (2022) P2Y12 inhibitor or aspirin following dual antiplatelet therapy after percutaneous coronary intervention: a network meta-analysis. JACC Cardiovasc Interv 15: 2239-2249. https://doi.org/10.1016/j.jcin.2022.08.009 ![]() |
[47] |
Andò G, Lombardo L, Alagna G, et al. (2024) Monotherapy with P2Y12-inhibitors after dual antiplatelet therapy: filling gaps in evidence. Int J Cardiol 401: 131893. https://doi.org/10.1016/j.ijcard.2024.131893 ![]() |
[48] | Alagna G, Mazzone P, Contarini M, et al. (2023) Dual antiplatelet therapy with parenteral P2Y12 inhibitors: rationale, evidence, and future directions. J Cardiovasc Dev Dis 10: 163. https://doi.org/10.3390/jcdd10040163 |
[49] |
Stone GW, Witzenbichler B, Weisz G, et al. (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382: 614-623. https://doi.org/10.1016/S0140-6736(13)61170-8 ![]() |
[50] |
Guedeney P, Claessen BE, Mehran R, et al. (2020) Coronary calcification and long-term outcomes according to drug-eluting stent generation. JACC Cardiovasc Interv 13: 1417-1428. https://doi.org/10.1016/j.jcin.2020.03.053 ![]() |
[51] |
Sangiorgi G, Rumberger JA, Severson A, et al. (1998) Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31: 126-133. https://doi.org/10.1016/s0735-1097(97)00443-9 ![]() |
[52] |
Criqui MH, Denenberg JO, Ix JH, et al. (2014) Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA 311: 271-278. https://doi.org/10.1001/jama.2013.282535 ![]() |
[53] |
Généreux P, Madhavan MV, Mintz GS, et al. (2014) Relation between coronary calcium and major bleeding after percutaneous coronary intervention in acute coronary syndromes (from the acute catheterization and urgent intervention triage strategy and harmonizing outcomes with revascularization and stents in acute myocardial infarction trials). Am J Cardiol 113: 930-935. https://doi.org/10.1016/j.amjcard.2013.11.053 ![]() |
[54] |
Généreux P, Redfors B, Witzenbichler B, et al. (2017) Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. Int J Cardiol 231: 61-67. https://doi.org/10.1016/j.ijcard.2016.12.150 ![]() |
[55] |
Giustino G, Mastoris I, Baber U, et al. (2016) Correlates and impact of coronary artery calcifications in women undergoing percutaneous coronary intervention with drug-eluting stents: from the Women in Innovation and Drug-Eluting Stents (WIN-DES) collaboration. JACC Cardiovasc Interv 9: 1890-1901. https://doi.org/10.1016/j.jcin.2016.06.022 ![]() |
[56] |
Lee MS, Yang T, Lasala J, et al. (2016) Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel-eluting stents: two-year clinical outcomes of paclitaxel-eluting stents in patients from the ARRIVE program. Catheter Cardiovasc Interv 88: 891-897. https://doi.org/10.1002/ccd.26395 ![]() |
[57] |
Huisman J, van der Heijden LC, Kok MM, et al. (2016) Impact of severe lesion calcification on clinical outcome of patients with stable angina, treated with newer generation permanent polymer-coated drug-eluting stents: a patient-level pooled analysis from TWENTE and DUTCH PEERS (TWENTE II). Am Heart J 175: 121-129. https://doi.org/10.1016/j.ahj.2016.02.012 ![]() |
[58] |
Bourantas CV, Zhang YJ, Garg S, et al. (2014) Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. Heart 100: 1158-1164. https://doi.org/10.1136/heartjnl-2013-305180 ![]() |
[59] |
Silvain J, Lattuca B, Beygui F, et al. (2020) Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet 396: 1737-1744. https://doi.org/10.1016/S0140-6736(20)32236-4 ![]() |
[60] |
Yeh RW, Secemsky EA, Kereiakes DJ, et al. (2016) Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 315: 1735-1749. https://doi.org/10.1001/jama.2016.3775 ![]() |
[61] |
Wallentin L, Becker RC, Budaj A, et al. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045-1057. https://doi.org/10.1056/NEJMoa0904327 ![]() |
[62] |
Mehilli J, Baquet M, Hochholzer W, et al. (2020) Randomized comparison of intensified and standard P2Y12-receptor-inhibition before elective percutaneous coronary intervention: the SASSICAIA trial. Circ Cardiovasc Interv 13: e008649. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008649 ![]() |
[63] |
Harrington RA, Stone GW, McNulty S, et al. (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361: 2318-2329. https://doi.org/10.1056/NEJMoa0908628 ![]() |
[64] |
Lattuca B, Mazeau C, Cayla G, et al. (2024) Ticagrelor vs clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome. JACC Cardiovasc Interv 17: 359-370. https://doi.org/10.1016/j.jcin.2023.12.011 ![]() |
[65] |
Mehran R, Rao SV, Bhatt DL, et al. (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123: 2736-2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449 ![]() |
[66] |
Dangas G, Baber U, Sharma S, et al. (2020) Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol 75: 2414-2424. https://doi.org/10.1016/j.jacc.2020.03.011 ![]() |
[67] |
Lhermusier T, Motreff P, Bataille V, et al. (2023) Ticagrelor in rotational atherectomy to reduce TROPonin enhancement: the TIRATROP study, a randomized controlled trial. J Clin Med 12: 1445. https://doi.org/10.3390/jcm12041445 ![]() |
[68] |
Amsterdam EA, Wenger NK, Brindis RG, et al. (2014) 2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 64: e139-e228. https://doi.org/10.1016/j.jacc.2014.09.017 ![]() |
[69] |
Ellis SG, Popma JJ, Buchbinder M, et al. (1994) Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 89: 882-892. https://doi.org/10.1161/01.cir.89.2.882 ![]() |
[70] |
Reisman M, Shuman BJ, Harms V (1998) Analysis of heat generation during rotational atherectomy using different operational techniques. Cathet Cardiovasc Diagn 44: 453-455. https://doi.org/10.1002/(sici)1097-0304(199808)44:4<453::aid-ccd21>3.0.co;2-i ![]() |
[71] |
Nienhuis MB, Ottervanger JP, Bilo HJG, et al. (2008) Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 71: 318-324. https://doi.org/10.1002/ccd.21345 ![]() |
[72] |
Tricoci P, Leonardi S, White J, et al. (2013) Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. J Am Coll Cardiol 62: 242-251. https://doi.org/10.1016/j.jacc.2013.04.043 ![]() |
[73] |
Safarian H, Alidoosti M, Shafiee A, et al. (2014) The SYNTAX score can predict major adverse cardiac events following percutaneous coronary intervention. Heart Views 15: 99-105. https://doi.org/10.4103/1995-705X.151081 ![]() |
[74] |
Lawton JS, Tamis-Holland JE, Bangalore S, et al. (2022) 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145: e4-e17. https://doi.org/10.1161/CIR.0000000000001039 ![]() |
[75] |
Leonardi S, Gragnano F, Carrara G, et al. (2021) Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes. J Am Coll Cardiol 77: 375-388. https://doi.org/10.1016/j.jacc.2020.11.046 ![]() |
[76] |
Valgimigli M, Smits PC, Frigoli E, et al. (2022) Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J 43: 3100-3114. https://doi.org/10.1093/eurheartj/ehac284 ![]() |
[77] |
Gragnano F, Mehran R, Branca M, et al. (2023) P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol 81: 537-552. https://doi.org/10.1016/j.jacc.2022.11.041 ![]() |
[78] |
Valgimigli M, Gragnano F, Branca M, et al. (2021) P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ 373: n1332. https://doi.org/10.1136/bmj.n1332 ![]() |
[79] |
Collet JP, Thiele H, Barbato E, et al. (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42: 1289-1367. https://doi.org/10.1093/eurheartj/ehaa575 ![]() |
[80] |
Valgimigli M, Frigoli E, Heg D, et al. (2021) Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 385: 1643-1655. https://doi.org/10.1056/NEJMoa2108749 ![]() |
[81] |
Serruys PW, Takahashi K, Chichareon P, et al. (2019) Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. Eur Heart J 40: 2595-2604. https://doi.org/10.1093/eurheartj/ehz453 ![]() |
[82] |
Yamamoto K, Watanabe H, Morimoto T, et al. (2021) Very Short dual antiplatelet therapy after drug-eluting stent implantation in patients who underwent complex percutaneous coronary intervention: insight from the STOPDAPT-2 trial. Circ Cardiovasc Interv 14: e010384. https://doi.org/10.1161/CIRCINTERVENTIONS.120.010384 ![]() |
[83] |
Lee SJ, Lee YJ, Kim BK, et al. (2021) Ticagrelor monotherapy versus ticagrelor with aspirin in acute coronary syndrome patients with a high risk of ischemic events. Circ Cardiovasc Interv 14: e010812. https://doi.org/10.1161/CIRCINTERVENTIONS.121.010812 ![]() |
[84] |
Roh JW, Hahn JY, Oh JH, et al. (2021) P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: a post-hoc analysis of SMART-CHOICE randomized clinical trial. Cardiol J 28: 855-863. https://doi.org/10.5603/CJ.a2021.0101 ![]() |
[85] |
Franzone A, McFadden E, Leonardi S, et al. (2019) Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol 74: 2223-2234. https://doi.org/10.1016/j.jacc.2019.08.1038 ![]() |
[86] |
Vranckx P, Valgimigli M, Jüni P, et al. (2018) Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet 392: 940-949. https://doi.org/10.1016/S0140-6736(18)31858-0 ![]() |
[87] |
Watanabe H, Domei T, Morimoto T, et al. (2019) Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 321: 2414-2427. https://doi.org/10.1001/jama.2019.8145 ![]() |
[88] |
Hahn JY, Song YB, Oh JH, et al. (2019) Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 321: 2428-2437. https://doi.org/10.1001/jama.2019.8146 ![]() |
[89] |
Mehran R, Baber U, Sharma SK, et al. (2019) Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 381: 2032-2042. https://doi.org/10.1056/NEJMoa1908419 ![]() |
[90] |
Kim BK, Hong SJ, Cho YH, et al. (2020) Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 323: 2407-2416. https://doi.org/10.1001/jama.2020.7580 ![]() |
[91] |
Natsuaki M, Watanabe H, Morimoto T, et al. (2024) An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation 149: 585-600. https://doi.org/10.1161/CIRCULATIONAHA.123.066720 ![]() |
[92] |
Nakamura M, Kimura K, Kimura T, et al. (2020) JCS 2020 guideline focused update on antithrombotic therapy in patients with coronary artery disease. Circ J 84: 831-865. https://doi.org/10.1253/circj.CJ-19-1109 ![]() |
[93] |
Ueki Y, Karagiannis A, Zanchin C, et al. (2019) Validation of high-risk features for stent-related ischemic events as endorsed by the 2017 DAPT guidelines. JACC Cardiovasc Interv 12: 820-830. https://doi.org/10.1016/j.jcin.2018.12.005 ![]() |
[94] | Yamamoto K, Shiomi H, Morimoto T, et al. (2021) Ischemic and bleeding risk after complex percutaneous coronary intervention in patients with or without high bleeding risk. Catheter Cardiovasc Interv 97: E758-E770. https://doi.org/10.1002/ccd.29335 |
[95] |
Yamamoto K, Natsuaki M, Watanabe H, et al. (2024) An aspirin-free strategy for immediate treatment following complex percutaneous coronary intervention. JACC Cardiovasc Interv 17: 1119-1130. https://doi.org/10.1016/j.jcin.2024.03.017 ![]() |
[96] |
Valgimigli M, Gragnano F, Branca M, et al. (2024) Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis. JAMA Cardiol 9: 437-448. https://doi.org/10.1001/jamacardio.2024.0133 ![]() |
[97] |
Watanabe H, Morimoto T, Natsuaki M, et al. (2022) Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol 7: 407-417. https://doi.org/10.1001/jamacardio.2021.5244 ![]() |
[98] |
Capodanno D, Baber U, Bhatt DL, et al. (2022) P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat Rev Cardiol 19: 829-844. https://doi.org/10.1038/s41569-022-00725-6 ![]() |
[99] |
Capodanno D, Mehran R, Krucoff MW, et al. (2023) Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium. Circulation 147: 1933-1944. https://doi.org/10.1161/CIRCULATIONAHA.123.064473 ![]() |
[100] |
Vrints C, Andreotti F, Koskinas KC, et al. (2024) 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J 45: 3415-3537. https://doi.org/10.1093/eurheartj/ehae177 ![]() |
[101] |
Cuisset T, Deharo P, Quilici J, et al. (2017) Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38: 3070-3078. https://doi.org/10.1093/eurheartj/ehx175 ![]() |
[102] |
Notarangelo FM, Maglietta G, Bevilacqua P, et al. (2018) Pharmacogenomic approach to selecting antiplatelet therapy in patients with acute coronary syndromes: the PHARMCLO trial. J Am Coll Cardiol 71: 1869-1877. https://doi.org/10.1016/j.jacc.2018.02.029 ![]() |
[103] |
Kim CJ, Park MW, Kim MC, et al. (2021) Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet 398: 1305-1316. https://doi.org/10.1016/S0140-6736(21)01445-8 ![]() |
[104] |
Sibbing D, Aradi D, Jacobshagen C, et al. (2017) A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial. Thromb Haemost 117: 188-195. https://doi.org/10.1160/TH16-07-0557 ![]() |
[105] |
Claassens DMF, Vos GJA, Bergmeijer TO, et al. (2019) A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med 381: 1621-1631. https://doi.org/10.1056/NEJMoa1907096 ![]() |
[106] |
Lee JM, Cho DK, Hahn JY, et al. (2016) Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy after percutaneous coronary intervention in patients with acute coronary syndromes (SMART-DATE) prospective multicenter randomized trial. Am Heart J 182: 1-8. https://doi.org/10.1016/j.ahj.2016.07.022 ![]() |
[107] |
Camaro C, Damen SAJ, Brouwer MA, et al. (2016) Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial. Am Heart J 178: 37-44. https://doi.org/10.1016/j.ahj.2016.04.016 ![]() |
[108] |
Kedhi E, Fabris E, van der Ent M, et al. (2018) Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 363: k3793. https://doi.org/10.1136/bmj.k3793 ![]() |
[109] |
Hong SJ, Lee SJ, Suh Y, et al. (2024) Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation 149: 562-573. https://doi.org/10.1161/CIRCULATIONAHA.123.066943 ![]() |
[110] |
Ge Z, Kan J, Gao X, et al. (2024) Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet 403: 1866-1878. https://doi.org/10.1016/S0140-6736(24)00473-2 ![]() |
[111] |
Gragnano F, Cao D, Pirondini L, et al. (2023) P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. J Am Coll Cardiol 82: 89-105. https://doi.org/10.1016/j.jacc.2023.04.051 ![]() |
[112] |
Chiarito M, Sanz-Sánchez J, Cannata F, et al. (2020) Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 395: 1487-1495. https://doi.org/10.1016/S0140-6736(20)30315-9 ![]() |
[113] |
Bhatt DL (2023) Optimal antiplatelet therapy revisited: When is a single better than a double?. J Am Coll Cardiol 81: 553-556. https://doi.org/10.1016/j.jacc.2022.11.040 ![]() |